{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:50:20Z","timestamp":1789692620499,"version":"4.0.1"},"reference-count":46,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"clinical research grant in aid by Tokyo Medical University","award":["22K09821"],"award-info":[{"award-number":["22K09821"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: To investigate associations among the aqueous humor levels of novel inflammatory factors, including FMS-related tyrosine kinase 3 ligand (Flt-3L), fractalkine, CXC chemokine ligand 16 (CXCL-16), and endocan-1; the severity of macular edema in central retinal vein occlusion (CRVO); and the prognosis of CRVO with macular edema after antivascular endothelial growth factor (VEGF) therapy. Materials and Methods: Aqueous humor was obtained during anti-VEGF treatment with intravitreal ranibizumab injection (IRI) in patients with CRVO and macular edema (n = 19) and during cataract surgery in patients with cataracts (controls, n = 20), and the levels of VEGF and novel inflammatory factors were measured. Macular edema was evaluated by central macular thickness (CMT) and neurosensory retinal thickness (TNeuro), and improvement was evaluated by calculating the percentage change in CMT and TNeuro from before to 1 month after IRI. Results: The levels of VEGF and the novel inflammatory factors were significantly higher in the CRVO group, and the levels of Flt-3L, CXCL-16, and endocan-1 were significantly correlated with each other and with the aqueous flare value. Baseline levels of Flt-3L, CXCL-16, and endocan-1 had a significantly negative correlation with the change in CMT, and the baseline level of CXCL-16 was significantly negatively correlated with the change in TNeuro. Conclusions: Relations among novel inflammatory factors should be further investigated. These findings may help improve understanding of macular edema in CRVO patients and aid the development of new treatments targeting novel inflammatory factors.<\/jats:p>","DOI":"10.3390\/medicina60010004","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T11:17:24Z","timestamp":1702984644000},"page":"4","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Role of Novel Inflammatory Factors in Central Retinal Vein Occlusion with Macular Edema"],"prefix":"10.3390","volume":"60","author":[{"given":"Kanako","family":"Yasuda","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-3063","authenticated-orcid":false,"given":"Hidetaka","family":"Noma","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Mimura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8606, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Nonaka","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akemi","family":"Ofusa","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Shimura","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hachioji Medical Center, Tokyo Medical University, 1163, Tatemachi, Hachioji 193-0998, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Noma, H., Yasuda, K., and Shimura, M. (2020). Cytokines and Pathogenesis of Central Retinal Vein Occlusion. J. Clin. Med., 9.","DOI":"10.3390\/jcm9113457"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/mt.2008.10","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: Implication of VEGF as a critical stimulator","volume":"16","author":"Campochiaro","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.ophtha.2009.04.038","article-title":"Monitoring ocular drug therapy by analysis of aqueous samples","volume":"116","author":"Campochiaro","year":"2009","journal-title":"Ophthalmology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1755-3768.2009.01524.x","article-title":"Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion","volume":"88","author":"Noma","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"857380","DOI":"10.1155\/2013\/857380","article-title":"Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy","volume":"2013","author":"Azzolini","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.ophtha.2011.12.005","article-title":"Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ophtha.2014.01.027","article-title":"Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: Two-year results from the COPERNICUS study","volume":"121","author":"Heier","year":"2014","journal-title":"Ophthalmology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.oret.2017.05.016","article-title":"Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study","volume":"2","author":"Larsen","year":"2018","journal-title":"Ophthalmol. Retina"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00417-009-1167-6","article-title":"Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion","volume":"248","author":"Ach","year":"2010","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.ophtha.2010.03.060","article-title":"Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: Two-year outcomes","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/IAE.0b013e3182993d74","article-title":"Pentraxin 3 and other inflammatory factors in central retinal vein occlusion and macular edema","volume":"34","author":"Noma","year":"2014","journal-title":"Retina"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"659735","DOI":"10.3389\/fphar.2021.659735","article-title":"FMS-Related Tyrosine Kinase 3 Ligand Promotes Radioresistance in Esophageal Squamous Cell Carcinoma","volume":"12","author":"Zhu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/10428194.2020.1834091","article-title":"FLT3 ligand in acute myeloid leukemia: A simple test with deep implications","volume":"62","author":"Peterlin","year":"2021","journal-title":"Leuk. Lymphoma Soc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.ircmb.2019.08.002","article-title":"Origin and development of classical dendritic cells","volume":"349","author":"Guermonprez","year":"2019","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.autrev.2013.09.010","article-title":"Fms-like tyrosine kinase 3 ligand-dependent dendritic cells in autoimmune inflammation","volume":"13","author":"Ramos","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/EJE-22-0247","article-title":"Novel inflammatory biomarkers in thyroid eye disease","volume":"187","author":"Ueland","year":"2022","journal-title":"Eur. J. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/art.37981","article-title":"Evidence that CXCL16 is a potent mediator of angiogenesis and is involved in endothelial progenitor cell chemotaxis: Studies in mice with K\/BxN serum-induced arthritis","volume":"65","author":"Isozaki","year":"2013","journal-title":"Arthritis Rheumatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"R18","DOI":"10.1186\/ar3242","article-title":"Dysregulated expression of MIG\/CXCL9, IP-10\/CXCL10 and CXCL16 and their receptors in systemic sclerosis","volume":"13","author":"Rabquer","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hald, S.M., Kiselev, Y., Al-Saad, S., Richardsen, E., Johannessen, C., Eilertsen, M., Kilvaer, T.K., Al-Shibli, K., Andersen, S., and Busund, L.T. (2015). Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: Combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1446-z"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pan.2015.01.004","article-title":"The chemokine ligand CXCL16 is an indicator of bacterial infection in necrotizing pancreatitis","volume":"15","author":"Wittel","year":"2015","journal-title":"Pancreatology"},{"key":"ref_21","first-page":"25","article-title":"Endocan or endothelial cell specific molecule-1 (ESM-1): A potential novel endothelial cell marker and a new target for cancer therapy","volume":"1","author":"Sarrazin","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1182\/blood-2009-07-230284","article-title":"Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching","volume":"115","author":"Strasser","year":"2010","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1158\/0008-5472.CAN-12-1855","article-title":"Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis","volume":"73","author":"Roudnicky","year":"2013","journal-title":"Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1177\/147323001003800213","article-title":"Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion","volume":"38","author":"Chen","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"(1993). Baseline and early natural history report: The central vein occlusion study. Arch. Ophthalmol., 111, 1087\u20131095.","DOI":"10.1001\/archopht.1993.01090080083022"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ajo.2011.04.006","article-title":"Soluble vascular endothelial growth factor receptor-2 and inflammatory factors in macular edema with branch retinal vein occlusion","volume":"152","author":"Noma","year":"2011","journal-title":"Am. J. Ophthalmol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/IAE.0b013e31821801de","article-title":"Vitreous inflammatory factors and serous macular detachment in branch retinal vein occlusion","volume":"32","author":"Noma","year":"2012","journal-title":"Retina"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000475603","article-title":"Aqueous Humor Levels of Soluble Vascular Endothelial Growth Factor Receptor and Inflammatory Factors in Diabetic Macular Edema","volume":"238","author":"Noma","year":"2017","journal-title":"Ophthalmologica"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16548","DOI":"10.1038\/s41598-018-35036-9","article-title":"Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema","volume":"8","author":"Mastropasqua","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_30","first-page":"756","article-title":"Comprehensive analysis of vitreous chemokines involved in ischemic retinal vein occlusion","volume":"25","author":"Zeng","year":"2019","journal-title":"Mol. Vis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cyto.2011.12.023","article-title":"Response patterns of cytokines\/chemokines in two murine strains after irradiation","volume":"58","author":"Zhang","year":"2012","journal-title":"Cytokine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000502276","article-title":"Plasma Levels, Temporal Trends and Clinical Associations between Biomarkers of Inflammation and Vascular Homeostasis after Pediatric Traumatic Brain Injury","volume":"41","author":"Lele","year":"2019","journal-title":"Dev. Neurosci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1136\/bjophthalmol-2019-315358","article-title":"Higher aqueous levels of matrix metalloproteinases indicated visual impairment in patients with retina vein occlusion after anti-VEGF therapy","volume":"105","author":"Luo","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1074\/jbc.271.34.20458","article-title":"ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines","volume":"271","author":"Lassalle","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3892\/or.2012.2012","article-title":"Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1\u03b1 in human colon carcinoma: Impact of ESM-1 on prognosis and its correlation with clinicopathological features","volume":"28","author":"Kim","year":"2012","journal-title":"Oncol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.167.6.3099","article-title":"Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a\/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1","volume":"167","author":"Scherpereel","year":"2001","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/jcp.24485","article-title":"Endocan elicits severe vascular inflammatory responses in vitro and in vivo","volume":"229","author":"Lee","year":"2014","journal-title":"J. Cell. Physiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.exer.2014.11.011","article-title":"Vascular changes in the developing rat retina in response to hypoxia","volume":"130","author":"Rathnasamy","year":"2015","journal-title":"Exp. Eye Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.4049\/jimmunol.164.6.3368","article-title":"Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa","volume":"164","author":"Muehlhoefer","year":"2000","journal-title":"J. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.5551\/jat.11.15","article-title":"Regulation of CX3CL1\/fractalkine expression in endothelial cells","volume":"11","author":"Imaizumi","year":"2004","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/j.cca.2011.03.036","article-title":"Fractalkine\/CX3CR1 and atherosclerosis","volume":"412","author":"Liu","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00005-016-0395-9","article-title":"Role of CX3CL1 in Diseases","volume":"64","author":"Liu","year":"2016","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1167\/iovs.07-0187","article-title":"Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis","volume":"48","author":"You","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ophtha.2012.11.011","article-title":"Predictive value in retinal vein occlusions of early versus late or incomplete ranibizumab response defined by optical coherence tomography","volume":"120","author":"Bhisitkul","year":"2013","journal-title":"Ophthalmology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1874364101307010011","article-title":"Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography","volume":"7","author":"Koss","year":"2013","journal-title":"Open Ophthalmol. J."},{"key":"ref_46","first-page":"824","article-title":"Real-World Outcomes of Ranibizumab Treatment in French Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion: 24-Month Results from the BOREAL-RVO Study","volume":"66","author":"Girmens","year":"2023","journal-title":"Ophthalmic Res."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:41:42Z","timestamp":1760132502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["medicina60010004"],"URL":"https:\/\/doi.org\/10.3390\/medicina60010004","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]}}}